Skip to main content
. 2015 Jan 23;7:51–63. doi: 10.2147/CMAR.S72814

Table 5.

Active and recruiting trials investigating specific molecular therapies in MPM

Agent Target Mechanism Goals of study Trial ID Sponsor
Vorinostat Histone deacetylase inhibitor Prevents gene transcription by maintaining chromatin condensed Randomized Phase II: progression after first-line chemo NCT01353482; withdrawn Merck
Ganetespib HSP90 inhibitor Cell cycle arrest Phase I–II: combination with chemo NCT01590160 University College, London/UK
Bortezomib Proteasome inhibitor Inhibits NF-κB pathway Phase II: bortezomib and oxaliplatin after failure of chemo NCT00996385 Columbia University/USA
ADI-PEG20 (arginine deiminase) Depletion of arginine Depletion of extracellular arginine interferes with tumor metabolism while tumor cells frequently down regulate ability to synthesize arginine Phase II: effect of ADI-PEG 20 alone
Phase I: ADI-PEG20 combination with chemo
NCT01279967
NCT02029690
Barts and The London NHS Trust Polaris
Everolimus Target of rapamycin Independently interferes with distal steps of EGFR pathway Phase II: single drug NCT00770120 NCI
Onconase/ranpirnase Inhibits NF-κB pathway Phase III: doxorubicin +/− onconase NCT00003034; unknown status NCI
NGR-TNF Vascular endothelium Recombinant TNF fused with a peptide recognizing endothelial cell-surface receptors Phase II: intravenous TNF given
Phase III: together with second-line chemo
NCT01358084
NCT01098266
MolMed SpA

Abbreviations: chemo, chemotherapy; EGFR, epidermal growth factor receptor; ID, identification number; MPM, malignant pleural mesothelioma; NCI, National Cancer Institute; NF-κB, nuclear factor kappa-B; TNF, tumor necrosis factor.